

# Fibrosis - Pipeline Review, H2 2017

<https://marketpublishers.com/r/F6C62D8E2A0EN.html>

Date: September 2017

Pages: 122

Price: US\$ 2,000.00 (Single User License)

ID: F6C62D8E2A0EN

## Abstracts

Fibrosis - Pipeline Review, H2 2017

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosis - Pipeline Review, H2 2017, provides an overview of the Fibrosis (Musculoskeletal Disorders) pipeline landscape.

Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued

projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 29, 17 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosis (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Fibrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Fibrosis (Musculoskeletal Disorders) therapeutics

based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosis (Musculoskeletal Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Fibrosis (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Fibrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction
Global Markets Direct Report Coverage
Fibrosis - Overview
Fibrosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fibrosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibrosis - Companies Involved in Therapeutics Development
Accelaron Pharma Inc
Aelis Farma SAS
Anima Biotech Ltd
Bristol-Myers Squibb Company
Cellmid Ltd
Clementia Pharmaceuticals Inc
Complexa Inc
Confo Therapeutics
EA Pharma Co Ltd
Five Prime Therapeutics Inc
Genfit SA
GlycoMimetics Inc
iBio Inc
Inception Sciences Inc
Isarna Therapeutics GmbH
Kadmon Corp LLC
Kalyra Pharmaceuticals Inc
Morphic Therapeutic Inc
Neumedicines Inc
Novartis AG
Palatin Technologies Inc
Proximagen Ltd

Redx Pharma Plc  
Ribomic Inc  
Scholar Rock Inc  
SciFluor Life Sciences LLC  
SK Chemicals Co Ltd  
Symic Biomedical Inc  
Fibrosis - Drug Profiles  
ACE-2798 - Drug Profile  
AEF-0118 - Drug Profile  
AK-002 - Drug Profile  
Antisense RNAi Oligonucleotide to Inhibit HSP47 for Fibrosis - Drug Profile  
CAB-101 - Drug Profile  
CALY-001 - Drug Profile  
CWHM-12 - Drug Profile  
Drugs for Fibrosis - Drug Profile  
elafibranor - Drug Profile  
G-XXX - Drug Profile  
IB-DMD - Drug Profile  
IBIOCFB-03 - Drug Profile  
ISTH-1106 - Drug Profile  
KL-01045 - Drug Profile  
Monoclonal Antibodies for Fibrosis - Drug Profile  
Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis - Drug Profile  
Monoclonal Antibody 2 for Fibrosis - Drug Profile  
Monoclonal Antibody for Fibrotic Scar - Drug Profile  
Monoclonal Antibody to Activate BMP7 for Fibrosis - Drug Profile  
NCE-401 - Drug Profile  
Neumomir - Drug Profile  
NMIL-121 - Drug Profile  
PAT-048 - Drug Profile  
phenylbutyrate - Drug Profile  
PL-5028 - Drug Profile  
PRI-724 - Drug Profile  
Proteins for Central Nervous System Disorders and Fibrosis - Drug Profile  
RBM-003 - Drug Profile  
RBM-007 - Drug Profile  
SB-061 - Drug Profile  
Small Molecule for Fibrosis - Drug Profile  
Small Molecule for Fibrosis - Drug Profile

Small Molecule to Antagonize CCR2 and CCR5 for Fibrotic Diseases - Drug Profile

Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile

Small Molecule to Inhibit MGAT2 for Metabolic Disorders and Fibrotic Diseases - Drug Profile

Small Molecule to Inhibit MicroRNA for Vascular Fibrosis - Drug Profile

Small Molecule to Inhibit ROCK2 for Fibrotic Diseases - Drug Profile

Small Molecules for Fibrosis - Drug Profile

Small Molecules for Fibrosis - Drug Profile

Small Molecules for Fibrosis - Drug Profile

Small Molecules for Fibrosis - Drug Profile

Small Molecules for Fibrosis - Drug Profile

Small Molecules for Fibrosis and Inflammatory Diseases - Drug Profile

Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile

Small Molecules to Agonize GPCR for Fibrosis - Drug Profile

Small Molecules to Agonize RARG for Fibrosis - Drug Profile

Small Molecules to Antagonize Integrin Alpha V for Fibrosis - Drug Profile

Small Molecules to Inhibit Galectin-9 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile

Small Molecules to Inhibit SMURF2 for Fibrosis and Oncology - Drug Profile

SRI-31277 - Drug Profile

ST-2001 - Drug Profile

ST-2022 - Drug Profile

Synthetic Peptides to Inhibit TGFb for Fibrosis and Oncology - Drug Profile

TTX-330 - Drug Profile

X-165 - Drug Profile

XOMA-089 - Drug Profile

Fibrosis - Dormant Projects

Fibrosis - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Fibrosis, H2 2017  
Number of Products under Development by Companies, H2 2017  
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017  
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017  
Number of Products under Development by Universities/Institutes, H2 2017  
Products under Development by Companies, H2 2017  
Products under Development by Companies, H2 2017 (Contd..1), H2 2017  
Products under Development by Companies, H2 2017 (Contd..2), H2 2017  
Products under Development by Universities/Institutes, H2 2017  
Number of Products by Stage and Target, H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017  
Number of Products by Stage and Route of Administration, H2 2017  
Number of Products by Stage and Molecule Type, H2 2017  
Fibrosis - Pipeline by Acceleron Pharma Inc, H2 2017  
Fibrosis - Pipeline by Aelis Farma SAS, H2 2017  
Fibrosis - Pipeline by Anima Biotech Ltd, H2 2017  
Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2017  
Fibrosis - Pipeline by Cellmid Ltd, H2 2017  
Fibrosis - Pipeline by Clementia Pharmaceuticals Inc, H2 2017  
Fibrosis - Pipeline by Complexa Inc, H2 2017  
Fibrosis - Pipeline by Confo Therapeutics, H2 2017  
Fibrosis - Pipeline by EA Pharma Co Ltd, H2 2017  
Fibrosis - Pipeline by Five Prime Therapeutics Inc, H2 2017  
Fibrosis - Pipeline by Genfit SA, H2 2017  
Fibrosis - Pipeline by GlycoMimetics Inc, H2 2017  
Fibrosis - Pipeline by iBio Inc, H2 2017  
Fibrosis - Pipeline by Inception Sciences Inc, H2 2017  
Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2017  
Fibrosis - Pipeline by Kadmon Corp LLC, H2 2017  
Fibrosis - Pipeline by Kalyra Pharmaceuticals Inc, H2 2017  
Fibrosis - Pipeline by Morphic Therapeutic Inc, H2 2017  
Fibrosis - Pipeline by Neumedicines Inc, H2 2017  
Fibrosis - Pipeline by Novartis AG, H2 2017

Fibrosis - Pipeline by Palatin Technologies Inc, H2 2017  
Fibrosis - Pipeline by Proximagen Ltd, H2 2017  
Fibrosis - Pipeline by Redx Pharma Plc, H2 2017  
Fibrosis - Pipeline by Ribomic Inc, H2 2017  
Fibrosis - Pipeline by Scholar Rock Inc, H2 2017  
Fibrosis - Pipeline by SciFluor Life Sciences LLC, H2 2017  
Fibrosis - Pipeline by SK Chemicals Co Ltd, H2 2017  
Fibrosis - Pipeline by Symic Biomedical Inc, H2 2017  
Fibrosis - Dormant Projects, H2 2017  
Fibrosis - Dormant Projects, H2 2017 (Contd..1), H2 2017  
Fibrosis - Dormant Projects, H2 2017 (Contd..2), H2 2017



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Fibrosis, H2 2017  
Number of Products under Development by Companies, H2 2017  
Number of Products under Development by Universities/Institutes, H2 2017  
Number of Products by Top 10 Targets, H2 2017  
Number of Products by Stage and Top 10 Targets, H2 2017  
Number of Products by Top 10 Mechanism of Actions, H2 2017  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017  
Number of Products by Routes of Administration, H2 2017  
Number of Products by Stage and Routes of Administration, H2 2017  
Number of Products by Top 10 Molecule Types, H2 2017  
Number of Products by Stage and Top 10 Molecule Types, H2 2017

### COMPANIES MENTIONED

Acceleron Pharma Inc  
Aelis Farma SAS  
Anima Biotech Ltd  
Bristol-Myers Squibb Company  
Cellmid Ltd  
Clementia Pharmaceuticals Inc  
Complexa Inc  
Confo Therapeutics  
EA Pharma Co Ltd  
Five Prime Therapeutics Inc  
Genfit SA  
GlycoMimetics Inc  
iBio Inc  
Inception Sciences Inc  
Isarna Therapeutics GmbH  
Kadmon Corp LLC  
Kalyra Pharmaceuticals Inc  
Morphic Therapeutic Inc  
Neumedicines Inc  
Novartis AG  
Palatin Technologies Inc

Proximagen Ltd  
Redx Pharma Plc  
Ribomic Inc  
Scholar Rock Inc  
SciFluor Life Sciences LLC  
SK Chemicals Co Ltd  
Symic Biomedical Inc

## I would like to order

Product name: Fibrosis - Pipeline Review, H2 2017

Product link: <https://marketpublishers.com/r/F6C62D8E2A0EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F6C62D8E2A0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970